Pooled outcomes in more than 330 UroLift ® System subjects treated in a controlled setting were analyzed and reported by Claus Roehrborn et. al. PUL with the UroLift ® System was durable in most ...
WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX) (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature ...
Dear Dr. Roach: I’m 79, and for several years, I have been taking finasteride and tamsulosin for benign prostatic hyperplasia. (In the past, I underwent a TURP procedure, which I will never go through ...
Teleflex TFX recently announced the upcoming full market release of the Advanced Tissue Control (“ATC”) feature on its unified UroLift 2 System — a platformdesigned for the treatment of benign ...
LAS VEGAS -- A novel, non-ablative intervention for lower urinary tract symptoms (LUTS) produced rapid, durable symptom relief with no adverse effect on sexual function, long-term results from ...
Teleflex announces favorable results for UroLift™ in treating BPH, showing higher patient satisfaction and better early recovery compared to Rezūm. Teleflex Incorporated announced new results from the ...
This story is sponsored by Revere Health. Holmium Laser Enucleation of the Prostate (HoLEP) is rapidly becoming the gold standard surgical treatment for benign prostatic hyperplasia (BPH), and there ...
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has unveiled groundbreaking results from the CLEAR study, the first head-to-head randomized controlled trial comparing the UroLift™ System with Rezūm™ ...
Medicare will typically cover TURP surgery if a doctor determines it is medically necessary for treating benign prostatic hyperplasia (BPH). Coverage varies based on hospital status. Medicare Part A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results